Latest News and Press Releases
Want to stay updated on the latest news?
-
NurExone Biologic will present at the EVs Forum in Cambridge presents advances in exosome therapy for spinal cord injuries, highlighting ExoPTEN potential
-
NurExone partners with Dr. Reuter Investor Relations for European investor relations services. TSX approves NurExone's warrant amendments.
-
The FDA’s response indicated that the planned toxicity study strategy is acceptable under FDA guidelines and large-scale animal studies will not be required. The completed Pre-IND meeting with the...
-
TORONTO and HAIFA, Israel, Sept. 06, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing...
-
Completed the first tranche of a non-brokered private placement offering of units for gross proceeds of approximately CAD$1.3 million to extend cash runway into 2024Strengthened the Board of Directors...
-
Not for distribution to United States newswire services or for dissemination in the United States TORONTO and TEL AVIV, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV:...
-
TORONTO and TEL AVIV, Israel, July 20, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or the “Company”) is pleased to announce significant advancements in...
-
TORONTO and TEL AVIV, Israel, June 22, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. ("NurExone" or the "Company") (TSXV: NRX) (FSE: J90) (NRX.V), is pleased to report positive imaging results...
-
MUNICH, Germany and TEL AVIV, Israel, June 01, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX) (FSE: J90), a biopharmaceutical company developing...
-
TORONTO and TEL AVIV, Israel, May 24, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (the "Company" or "NurExone") (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing...